BioCryst's immune disorder drug succeeds in mid-stage trial

(Reuters) - BioCryst Pharmaceuticals Inc said its experimental drug for treating a rare immune disorder was effective in reducing the attacks of the disease in a mid-stage trial. The drug, BCX4161, was compared with a placebo and was being tested in patients with hereditary angioedema (HAE) – a genetic disease characterized by sudden attacks of swelling of the skin or the mucous membranes, which can be disfiguring, painful and life-threatening.



via Health News Headlines - Yahoo News http://ift.tt/1mjZBlb